Is imatinib FDA approved?
Novartis recently announced that the United States Food and Drug Administration (FDA) approved its signal transduction inhibitor Gleevec (imatinib mesylate) as an oral therapy for the treatment of patients with chronic myeloid leukemia (CML) in the blast crisis, accelerated phase or in chronic phase after failure of …
When was imatinib approved by FDA?
Approval Date: 5/20/2003.
Is imatinib FDA approved for GIST?
The FDA has granted imatinib mesylate (Gleevec) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST).
Who discovered imatinib?
Imatinib was invented in the late 1990s by biochemist Nicholas Lyndon then working for Ciba-Geigy (now Novartis), and its use to treat CML was driven by Brian Druker, an oncologist at the Dana-Farber Institute. The first clinical trial of Imatinib took place in 1998 and the drug received FDA approval in May 2001.
How does Gleevec work at the molecular level?
Gleevec, the thin molecule shown here in blue, has a specific shape which blocks the active site of the abnormal protein. By binding to the active site, Gleevec prevents the trigger protein from causing the release the white blood cells and alleviates the symptoms of the disease.
How does imatinib work in GIST?
This drug targets both the KIT and PDGFRA proteins, blocking their ability to help tumor cells grow and divide. In most GISTs, the cells have too much of one of these proteins. Most GISTs shrink when treated with imatinib. Some other tumors at least stop growing for a time.
Why is imatinib so effective?
Imatinib is well absorbed after oral administration with a bioavailability exceeding 90% [4]. It is extensively metabolized, principally by cytochrome P450 (CYP)3A4 and CYP3A5, and can competitively inhibit the metabolism of drugs that are CYP3A4 or CYP3A5 substrates.
